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Abstract
Background: Sorafenib is the first agent that has demonstrated an improved overall survival benefit in
advanced hepatocellular carcinoma (HCC), setting a new standard for first-line treatment. However, no
one has yet been able to predict sensitivity to sorafenib. Pre-treatment pERK level has been shown to be
associated with favorable response to such therapy in a phase II clinical study, indicating that pERK may be
a potential biomarker for treatment of HCC with sorafenib.
Methods: The effects of sorafenib and 5-fluorouracil (5-FU) on cell proliferation were evaluated by cell
viability assays in four HCC cell lines (SMMC-7721, MHCC97-L, MHCC97-H and HCCLM6) with different
metastatic potential and basal pERK expression levels. Expression levels of pERK were determined by
immunocytochemical quantification together with western blot analysis, and pERK density values were
also calculated. Correlation analyses were then carried out between the IC50 values of drugs and pERK
density values. After basal ERK phosphorylation was down-regulated with U0126 in MHCC97-H cells,
cellular responsiveness to sorafenib was assessed by cell viability assay.
Results: Basal pERK levels increased stepwise in cell lines in accordance with their metastatic potential.
Sorafenib inhibited ERK phosphorylation in a dose-dependent manner in all four cell lines at a
concentration between 5 and 20 μM, but the degree of inhibition was significantly different according to
their basal pERK expression level (P < 0.0001). In contrast, no significant change was observed after 5-FU
treatment. Correlation analyses between the IC50 values and pERK densities revealed that the effects of
sorafenib on cell proliferation were significantly correlated with basal pERK levels (Spearman r = -0.8671,
P = 0.0003). Resistance to 5-FU was also significantly associated with basal pERK expression in these HCC
cell lines (Spearman r = 0.7832, P = 0.0026). After the basal ERK phosphorylation level in MHCC97-H cells
was reduced with U0126, they were significantly less sensitive to sorafenib-mediated growth inhibition,
with an IC50 of 17.31 ± 1.62 μM versus 10.81 ± 1.24 μM (P = 0.0281).
Conclusion: In this in vitro study, pERK was confirmed to be a potential biomarker predictive of sensitivity
to sorafenib in treating HCC. The RAF/MEK/ERK pathway may be involved in drug resistance to traditional
chemotherapy in HCC.
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Background
Hepatocellular carcinoma (HCC) is the sixth most com-
mon malignancy worldwide and the third most common
cause of death from cancer, accounting for more than
626,000 new cases and 598,000 deaths per year. Of all
these cases, more than half are in China alone [1]. The dis-
ease is diagnosed at early stages in 30 to 40% of all
patients and is amenable to potentially curative treat-
ments, such as surgical therapies (resection and liver
transplantation) and locoregional procedures (radiofre-
quency ablation). Five-year survival rates of up to 60 to
70% can be achieved in well-selected patients [2]. How-
ever, disease diagnosed at an advanced stage or with pro-
gression after locoregional therapy has a dismal
prognosis, owing to the underlying liver disease and lack
of effective treatment options [3]. No systemic therapy
with traditional chemotherapy drugs has improved sur-
vival in patients with advanced hepatocellular carcinoma
[4].
Sorafenib (Nexavar, Bayer HealthCare Pharmaceuticals) is
an oral multikinase inhibitor that inhibits the serine-thre-
onine kinases Raf-1 and B-Raf, the receptor tyrosine
kinase activity of vascular endothelial growth factor
(VEGF) receptors 1, 2, and 3, and platelet-derived growth
factor receptor β [5]. It blocks tumor cell proliferation and
tumor angiogenesis, and increases the rate of apoptosis in
a wide range of tumor models by targeting the Raf/
mitogen-activated protein kinase kinase/extracellular sig-
nal-regulated kinase (RAF/MEK/ERK) and VEGF signaling
pathways [6]. The results of a phase III, randomized, pla-
cebo-controlled trial, the Sorafenib HCC Assessment Ran-
domized Protocol (SHARP) trial, were recently presented
[7]. In this trial, sorafenib demonstrated improved overall
survival and time to tumor progression in patients with
advanced HCC. This landmark study represents the first
agent that has demonstrated an improved overall survival
benefit in this disease and sets a new standard for the first-
line treatment of advanced HCC that has been approved
by the US Food and Drug Administration (FDA).
However, no one has yet predicted sensitivity to sorafenib
in the treatment of HCC. It is well known that phosphor-
ylated ERK (pERK) is a key downstream component of the
RAF/MEK/ERK signaling pathway. It can be translocated
to the nucleus after phosphorylation, where it leads to
changes in gene expression by phosphorylating and regu-
lating various transcription factors, such as Ets family
transcription factors (for example, Elk-1) [8]. In a phase II
study in 137 patients with advanced, inoperable HCC, of
which 33 had their pre-treatment pERK levels evaluated,
pre-treatment tumor pERK levels were correlated with the
time to tumor progression. Patients whose tumors
expressed higher baseline pERK levels had a longer time to
tumor progression following treatment with sorafenib
[9]. These data suggest that tumors containing higher lev-
els of pERK are more sensitive, or responsive, to sorafenib,
indicating that pERK may be a useful biomarker in treat-
ing HCC with sorafenib. Whether this marker will prove
to be predictive of response needs to be validated in future
studies.
To investigate the relationship between the effects of sor-
afenib on cell proliferation and basal pERK levels in HCC
cell lines, here we evaluate the effects of sorafenib on four
HCC tumor cell lines (SMMC-7721, MHCC97-L,
MHCC97-H and HCCLM6) with different metastatic
potentials and baseline pERK expression levels. A series of
human HCC cell lines with similar genetic backgrounds
yet dramatic differences in spontaneous metastatic behav-
iors, which had been established at the authors' institute
[10,11], provided a unique platform for this research.
Among these cell lines, SMMC-7721 is low-invasive and
non-metastatic. MHCC97-L and MHCC97-H are two dif-
ferent metastatic HCC cell clones isolated from the same
parent cell line MHCC97, which was derived from a nude
mouse model of human HCC metastasis (LCI-D20). The
LCI-D20 model was developed by orthotopic inoculation
of an intact tumour tissue of an intrahepatic disseminated
lesion from a 39-year-old Chinese male patient with HCC
(Zhongshan Hospital, Fudan University, Shanghai,
China) in whose serum abnormal alpha-fetoprotein and
HBsAg (hepatitis B surface antigen) were found. Sponta-
neous pulmonary metastasis occurred in 40% and 100%
of recipient nude mice after orthotopic transplantation of
MHCC97-L and MHCC97-H, respectively. HCCLM6 was
established from MHCC97-H by six rounds of in vivo
metastasis selection and produced further multiple exten-
sive metastases through both blood vessels and lymphatic
channels. Such characteristics make these cell lines valua-
ble for comparative study.
Materials and methods
Drug preparations
Sorafenib tosylate (Nexavar, [N-(3-trifluoromethyl-4-
chlorophenyl)-N-(4-(2-methylcarbamoylyridin-4-yl)oxy-
phenyl)urea]) was a gift from Bayer Schering Phama. The
MEK1/2 inhibitor U0126 was purchased from Cell Signal-
ing Technologies Inc. (Beverly, MA, USA). Sorafenib and
U0126 were dissolved in 100% dimethyl sulfoxide
(DMSO; Sigma, St Louis, MO, USA) and diluted with
RPMI 1640 or Dulbecco's modified Eagle's medium
(DMEM) to the desired concentration with a final DMSO
concentration of 0.1% (v/v) for in vitro studies. DMSO
was added to cultures at 0.1% (v/v) as a solvent control.
Fluorouracil injection was purchased from Shanghai
Xudong Haipu Pharmaceutical Co., Ltd (Shanghai,
China) and was diluted directly with cell culture media to
the desired concentration.BMC Medicine 2009, 7:41 http://www.biomedcentral.com/1741-7015/7/41
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Cell lines
SMMC-7721 human HCC tumor cells were obtained
from the Institute of Biochemistry and Cell Biology,
Shanghai Institutes for Biological Sciences, Chinese Acad-
emy of Sciences (Shanghai, China) and cultured in RPMI
1640. MHCC97-L, MHCC97-H and HCCLM6 human
HCC tumor cells were obtained from the Liver Cancer
Institute of Fudan University (Shanghai, China) and cul-
tured in DMEM. All cells were cultured at 37°C in 5% CO2
in culture media containing 10% fetal bovine serum.
Unless otherwise indicated, cell culture reagents were pur-
chased from GIBCO BRL Company (Grand Island, NE,
USA).
Immunocytochemical staining and quantification
Cells were plated in six-well plates with cover slips at 4 ×
105 per well. On the following day, cells were treated with
compounds indicated in the experiment. Briefly, cells
were exposed to 5, 10, or 20 μM sorafenib for 24 hours.
Cells were exposed to 20 μM U0126 for 6 hours. DMSO
was added to cultures at 0.1% (v/v) as a solvent control.
Cells were treated with 10, 20, or 50 mg/l 5-fluorouracil
(5-FU) for 48 hours. Cell culture medium without 5-FU
was used as a control. After being fixed in acetone and
blocked serially with IHC Biotin Block kit, 3% H2O2, and
10% normal goat serum, sections were incubated with the
mouse monoclonal antibody to ERK1 + ERK2 (Clone
MAPK-YT, Abcam, Cambridge, MA, USA) at 1:100 dilu-
tion overnight at 4°C. The UltraSensitive™ S-P stain sys-
tem (Maixin Biotechnology Development Co., Ltd,
Fuzhou, China) was applied according to the manufac-
turer's instructions. Sections were then developed in
diaminobenzidine solution and counterstained with
Mayer's hematoxylin. Negative controls were performed
by omitting the primary antibodies.
Sections were observed at 200× magnification in a com-
puterized image system composed of a Leica CCD camera
DFC420 connected to a Leica DM IRE2 microscope (Leica
Microsystems Imaging Solutions Ltd, Cambridge, United
Kingdom) and images were captured by the Leica QWin
Plus version 3 software under the same conditions. The
same protein quantification method was used for pERK
quantification with Image-Pro Plus version 6.2 software
(Media Cybernetics Inc., Bethesda, MD, USA) as Sun's
group reported [12]. The pERK density in each field was
calculated as [Integrated optical density of pERK-positive
objects/(Total field area – Blank area)]. The mean value of
pERK density in each group was calculated on six random
field samples from three independent experiments with
replicates per experiment. The expression rate of pERK
was calculated from pERK density and the expression rate
in the control group of each cell line was set as the 100%
baseline. Data within each group were analyzed statisti-
cally with one-way ANOVA and differences between cell
lines of sorafenib's pERK inhibition were analyzed by
two-way ANOVA, both of which were followed by Bonfer-
roni's multiple comparison test with SPSS 13.0 for Win-
dows (SPSS Inc. Chicago, IL, USA). P  < 0.05 was
considered significant.
Immunoblot analysis
Cells were plated at 6 × 105 cells per well in six-well plates.
On the following day, cells were treated with the same
methods as described above. After treatment, cells were
washed with cold phosphate-buffered saline and lysed
using RIPA lysis buffer containing 1 mM phenylmethyl-
sulfonyl fluoride (PMSF). Twenty micrograms of protein,
which was determined using a bicinchoninic acid protein
assay, from control and treated cell lysates was loaded on
5% and 12% SDS-PAGE gels, electrophoresed at a con-
stant voltage of 70 V for 2 hours, and transferred onto
PVDF membranes (0.45 μm) at a constant voltage of 80 V
for 2.5 hours. Blots were probed with a 1:1,000 dilution
of mouse monoclonal to ERK1 + ERK2 antibody (Clone
MAPK-YT, Abcam, Cambridge, MA, USA), a 1:3,000 dilu-
tion of anti-human β-actin monoclonal antibody, then
horseradish peroxidase-conjugated secondary antibody
(1:500) and detected by enhanced chemiluminescence
reagent (ECL kit, Pierce, Rockford, IL, USA). Unless other-
wise indicated, immunoblot reagents were purchased
from Beyotime Institute of Biotechnology (Shanghai,
China).
Cell viability assay
Cells were plated at 5,000 cells per well in 96-well micro-
titer plates and incubated overnight at 37°C in a humidi-
fied incubator containing 5% CO2. On the following day,
compounds were added to the wells indicated in the
experiment. Cells were exposed to sorafenib for 24 hours
at concentrations of 0.01, 0.1, 1, 2, 4, 5, 10, 15, 20, 25 or
30 μM, and to U0126 for 6 hours at concentrations of 1,
5, 10, 20, 50 or 100 μM. In the sequential combination
experiment, cells were pretreated with 20 μM U0126 for 6
hours and then exposed to sorafenib for a further 24
hours. DMSO was added to cultures at 0.1% (v/v) as a sol-
vent control. Cells were treated with 5-FU for 48 hours at
concentrations of 0.01, 0.1, 1, 5, 10, 20, 50, 100, 200, 500
or 1,000 mg/l. Cell culture medium without 5-FU was
used as a control. Cell viability was determined using the
Cell Counting Kit-8 (Dojindo Laboratories, Kumamoto,
Japan) according to the manufacturer's instructions [13].
IC50 values were calculated by nonlinear regression analy-
sis using GraphPad Prism version 5.0 software (GraphPad
Software, Inc., San Diego, CA, USA) [6], according to the
results of at least three independent experiments with four
replicates of each cell line per experiment. Differences in
cellular responsiveness to drugs were analyzed statistically
with two-way ANOVA with SPSS 13.0 for Windows (SPSS
Inc.). Spearman's rank correlation method was used forBMC Medicine 2009, 7:41 http://www.biomedcentral.com/1741-7015/7/41
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correlation analyses between pERK density values and
drugs' IC50 values of three independent experiments for
four cell lines with four replicates each (SPSS 13.0 for
Windows, SPSS Inc.). P < 0.05 was considered significant.
Results
Basal pERK levels in HCC cell lines increase stepwise with 
their metastatic potential
Basal pERK levels in four HCC cell lines were measured by
immunocytochemistry and image quantification. Immu-
nocytochemical analysis showed that pERK proteins were
found in both the nuclei and cytoplasm of tumor cells.
However, pERK in cell lines with higher metastatic poten-
tial seemed more inclined to be located in the nucleus,
with stronger staining intensity (Figure 1B–E). The results
of image quantification confirmed that baseline pERK was
differentially expressed in these HCC cell lines (P  <
0.0001, n = 6) and seemed to be correlated with their met-
astatic potential. The pERK density in SMMC-7721,
MHCC97-L, MHCC97-H and HCCLM6 cells was 0.042 ±
0.006, 0.081 ± 0.007, 0.329 ± 0.037 and 0.463 ± 0.084,
respectively. In metastatic MHCC97-H and HCCLM6
cells, pERK levels were significantly higher than in non-
metastatic SMMC-7721 cells (P < 0.0001, n = 6). Even
among the three metastatic cell lines, pERK levels were dif-
ferentially expressed and increased stepwise with their
metastatic potential (P < 0.0001, n = 6; Figure 1F).
Baseline ERK phosphorylation levels in these cancer cells
were also examined by western blot analysis. Consistent
with immunocytochemical analysis, the results demon-
strated that cancer cells with more invasive potential such
as HCCLM6 and MHCC97-H cells expressed higher levels
of pERK when compared to the relatively less invasive
MHCC97-L or SMMC-7721 cells (Figure 1G).
Effects of sorafenib on ERK phosphorylation inhibition are 
significantly associated with basal pERK levels in HCC cell 
lines
The pERK protein is best known as a key downstream
component of the RAF/MEK/ERK pathway. Changes in
the levels of ERK phosphorylation were determined by
immunocytochemical analysis in order to evaluate the
effects of sorafenib on this pathway. In our study, soraf-
enib could inhibit ERK phosphorylation in all four HCC
cell lines dose-dependently at a concentration between 5
and 20 μM (Figure 2A). After exposure to 5, 10 or 20 μM
sorafenib for 24 hours, the expression rate of pERK in
SMMC-7721 cells fell gradually to 81.88 ± 7.65%, 71.63 ±
10.80% and 17.47 ± 1.34%, respectively, and in HCCLM6
cells to 78.06 ± 4.66%, 28.12 ± 1.36% and 3.99 ± 0.19%,
respectively (Figure 2B). The expression rates in both cell
lines were significantly reduced when compared to each
DMSO control group (P = 0.0043, n = 6, and P < 0.0001,
n = 6, respectively). However, further statistical analyses
revealed the significant difference in the degree of the sor-
afenib effects in these HCC cell lines. Interestingly, the
sorafenib pERK inhibition effect in SMMC-7721 cells with
lower initial levels of pERK was significantly weaker when
compared to the other three HCC cell lines with relatively
higher basal pERK levels (P < 0.0001, n = 6; Figure 2B),
and it should be noted that this difference was mainly at
10 μM sorafenib. No significant difference was found in
MHCC97-L, MHCC97-H and HCCLM6 cells.
On the contrary, no significant change was observed after
5-FU treatment in MHCC97-H cells (Figure 3A–E). The
pERK expression rate was 102.3 ± 7.88%, 110.8 ± 6.60%,
and 101.1 ± 5.12%, respectively, after exposure to 10, 20
or 50 mg/l 5-FU for 48 hours, with no statistical difference
with the control group (P > 0.05, n = 6; Figure 3E). West-
ern blot analysis confirmed the same results above (Figure
3F).
Effects of sorafenib on cell proliferation are significantly 
correlated with basal pERK levels in HCC cell lines
The effects of sorafenib on cell proliferation were meas-
ured by the CCK-8 cell viability assay. According to our
results, sorafenib inhibited proliferation of all four HCC
cell lines in a dose-dependent manner as described in pre-
vious research [6], with an IC50 of 20.85 ± 2.81 μM, 10.38
± 1.52 μM, 10.70 ± 2.35 μM and 9.11 ± 2.44 μM in
SMMC-7721, MHCC97-L, MHCC97-H and HCCLM6
cells, respectively. As expected, SMMC-7721 cells, which
contain the lowest levels of pERK, were significantly less
sensitive to sorafenib-mediated growth inhibition than
the other three HCC cell lines with higher basal pERK lev-
els (P = 0.0018, n = 4; Figure 4A). Meanwhile, a significant
negative correlation (Spearman r = -0.8671, P = 0.0003, n
= 12) was observed between the IC50 values of sorafenib
in these HCC cell lines and their pERK density values (Fig-
ure 4C), indicating that the effects of sorafenib on cell pro-
liferation were significantly correlated with basal pERK
levels in these HCC cell lines.
Opposite results were observed with treatment with the
traditional chemotherapy drug 5-FU. 5-FU inhibited HCC
cell proliferation with an IC50 of 4.24 ± 0.87 mg/l, 79.71
± 24.49 mg/l, 41.21 ± 21.55 mg/l and 187.45 ± 78.05 mg/
l in SMMC-7721, MHCC97-L, MHCC97-H and HCCLM6
cells, respectively, with significant statistical differences (P
< 0.0001, n = 4). The SMMC-7721 cells, with lower pERK
expression, demonstrated a higher sensitivity to 5-FU.
However, MHCC97-L, MHCC97-H, and HCCLM6 cells,
with higher pERK expression, exhibited more resistance to
this drug. The ultimate inhibition rate before reaching a
plateau in these three cell lines was about 35%, 40%, and
45%, respectively, each compared to its control group
(Figure 4B). Furthermore, a significant correlation (Spear-
man r = 0.7832, P = 0.0026, n = 12) was observed betweenBMC Medicine 2009, 7:41 http://www.biomedcentral.com/1741-7015/7/41
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Basal pERK levels in hepatocellular carcinoma (HCC) cell lines increased stepwise in accordance with their metastatic potential Figure 1
Basal pERK levels in hepatocellular carcinoma (HCC) cell lines increased stepwise in accordance with their 
metastatic potential. (A-E) Immunocytochemical staining of pERK (200×). (A) Negative control. (B) SMMC-7721. (C) 
MHCC97-L. (D) MHCC97-H. (E) HCCLM6. (F) Quantification of basal pERK levels in different HCC cell lines. pERK density 
was quantified using Image-Pro Plus version 6.2 software as described in Materials and methods. Columns represent means of 
six samples in each group; bars indicate standard deviation; *, P < 0.05, when compared to the negative control. (G) Western 
blot analysis of pERK protein in different HCC cell lines.BMC Medicine 2009, 7:41 http://www.biomedcentral.com/1741-7015/7/41
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The degree of sorafenib's inhibition of ERK phosphorylation was significantly associated with basal pERK levels in hepatocellular  carcinoma (HCC) cell lines Figure 2
The degree of sorafenib's inhibition of ERK phosphorylation was significantly associated with basal pERK levels 
in hepatocellular carcinoma (HCC) cell lines. (A) Immunocytochemical staining of pERK (200×) after treatment with 
sorafenib for 24 hours in four HCC cell lines. (B) pERK expression rate in HCC cell lines after sorafenib treatment. pERK lev-
els were reduced after sorafenib treatment in all four cell lines, but the inhibition effect in SMMC-7721 cells, with lower levels 
of pERK, was significantly weaker when compared to the other three HCC cell lines with relatively higher basal pERK levels 
(two-way ANOVA, P < 0.0001, n = 6). The expression rate of pERK was calculated from pERK density determined as 
described in Materials and methods and the rate in each control group was set as the 100% baseline. Columns represent means 
of six samples in each group; bars indicate standard error.BMC Medicine 2009, 7:41 http://www.biomedcentral.com/1741-7015/7/41
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5-Fluorouracil (5-FU) hardly inhibited ERK phosphorylation in MHCC97-H cells Figure 3
5-Fluorouracil (5-FU) hardly inhibited ERK phosphorylation in MHCC97-H cells. (A-D) Immunocytochemical stain-
ing of pERK (200×) after treatment with 5-FU for 48 hours in MHCC97-H cells. (A) Culture medium without 5-FU was used as 
control. (B) 5-FU 10 mg/l. (C) 5-FU 20 mg/l. (D) 5-FU 50 mg/l. (E) pERK expression was not reduced after 5-FU treatment. 
The expression rate of pERK was calculated from pERK density determined as described in Materials and methods and the rate 
in the control group was set as the 100% baseline. Columns represenr means of six samples in each group; bars indicate stand-
ard deviation; *, P < 0.05, when compared to the control. (F) Western blot analysis of pERK protein in MHCC97-H cells after 
treatment with 5-FU for 48 hours.BMC Medicine 2009, 7:41 http://www.biomedcentral.com/1741-7015/7/41
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the IC50 values of 5-FU and pERK density values (Figure
4D), indicating that the resistance to 5-FU was signifi-
cantly associated with basal pERK expression in these
HCC cell lines.
Effects of MEK/ERK pathway inhibition and pERK 
reduction on sensitivity to sorafenib
To more directly determine the relationship between
pERK expression and sensitivity to sorafenib, we inhibited
the MEK/ERK pathway and reduced basal pERK expres-
sion in MHCC97-H cells via U0126, a selective inhibitor
of MEK 1 and MEK 2 [14], and then compared cellular
responsiveness to sorafenib to that of untreated cells. To
avoid possible direct growth inhibition by U0126, expo-
sure of cells to this drug was limited to 6 hours according
to our preliminary experiments. Quantification of cellular
pERK levels by immunocytochemical analysis indicated
that constitutive ERK phosphorylation was strongly
reduced in MHCC97-H cells after treatment with 20 μM
U0126 for 6 hours, relative to the level observed in the
Effects of sorafenib and resistance to 5-fluorouracil (5-FU) were significantly correlated with basal pERK levels in hepatocellular  carcinoma (HCC) cell lines Figure 4
Effects of sorafenib and resistance to 5-fluorouracil (5-FU) were significantly correlated with basal pERK levels 
in hepatocellular carcinoma (HCC) cell lines. (A) Sorafenib inhibited cell proliferation in different HCC cell lines. (B) 5-
FU inhibited cell proliferation in different HCC cell lines. Each value represents the average of four independent determinations 
with four replicates per experiment. Bars indicate standard error. (C) Correlation analysis between the IC50 values of soraf-
enib and pERK density values. (D) Correlation analysis between the IC50 values of 5-FU and pERK density values. The IC50 
value, at which 50% of cell growth is inhibited compared with control, was calculated by nonlinear regression analysis using 
GraphPad Prism version 5.0 software. pERK density was quantified using Image-Pro Plus version 6.2 software as described in 
Materials and methods. Spearman's rank correlation method was used for correlation analysis between pERK density values 
and drugs' IC50 values of three independent experiments for four cell lines with four replicates each. P < 0.05 was considered 
significant.BMC Medicine 2009, 7:41 http://www.biomedcentral.com/1741-7015/7/41
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untreated cells (60% inhibition; Figure 5A–C), which
induced almost no detectable systemic toxicity on cell
proliferation (Figure 5D).
In the following experiments, we compared sorafenib
responsiveness of MHCC97-H cells pretreated with 20 μM
U0126 for 6 hours to an untreated control. Cell viability
assay revealed that the pretreated cells were significantly
less sensitive to sorafenib-mediated growth inhibition,
with an IC50 of 17.31 ± 1.62 μM versus 10.81 ± 1.24 μM
(P = 0.0281, n = 6; Figure 5E). These results confirmed
that the RAF/MEK/ERK signaling pathway was essential
for sorafenib-mediated growth inhibition, and that the
sensitivity to sorafenib was directly related to the activa-
tion of this pathway and basal pERK expression in
MHCC97-H cells.
Discussion
It is well known that the RAF/MEK/ERK cascade is a key
signaling pathway involved in the regulation of normal
mammalian cell proliferation, survival and differentia-
tion. It couples signals from cell surface receptors to tran-
scription factors and regulates gene expression though a
phosphorylation cascade. Raf serine/threonine kinases
phosphorylate and activate the MEK1/2 dual-specificity
protein kinases, which then phosphorylate and activate
ERK1/2. Activated ERK is a downstream component of an
evolutionarily conserved signaling module that can be
translocated to the nucleus, where it phosphorylates and
regulates various transcription factors, ultimately leading
to changes in gene expression. Additionally, Ras family
small GTPases are key upstream activators of the RAF/
MEK/ERK pathway, which are often activated by upstream
molecules such as receptor tyrosine kinases (for example,
epidermal growth factor receptor, VEGF receptor and
transforming growth factor-α receptors) [8]. Mutation or
over-activation of related components in the RAF/MEK/
ERK cascade would lead to acceleration of cell prolifera-
tion and extension of survival, thus contributing to
human oncogenesis [15].
This pathway has been implicated in the molecular patho-
genesis of HCC. First of all, as an upstream activator of
this pathway, the Ras gene is mutationally activated in
30% of HCCs [16]. Second, Raf kinase over-expression
occurs in most HCCs. For example, in a study on HCC tis-
sue specimens, the Raf-1 gene was up-regulated in 50% of
22 HCC specimens and activated Raf-1 protein was over-
expressed in 100% of 30 HCC specimens [17]. Third, a
variety of upstream growth factors, such as epidermal
growth factor, VEGF, platelet-derived growth factor-β and
transforming growth factor-α, which are generally over-
expressed in HCC, can activate this pathway through
binding their receptor tyrosine kinases [8,18].
The pERK protein is a key downstream component of the
MEK/ERK cascade. In this study, basal levels of pERK were
determined by immunocytochemical analysis and west-
ern blot analysis in order to evaluate the activation of the
RAF/MEK/ERK pathway in four types of HCC cell lines
with different metastatic potential. The results revealed
that basal pERK levels increased stepwise in cell lines in
accordance with their metastatic potential, indicating that
the RAF/MEK/ERK pathway may be involved in tumor
invasion and metastasis in HCC, consistent with results of
previous studies [19].
Sorafenib is a multikinase inhibitor that inhibits the Raf
serine-threonine kinases and blocks the RAF/MEK/ERK
signaling pathway. Changes in the levels of pERK protein
were determined by immunocytochemical analysis in
these HCC tumor cells. Sorafenib inhibited ERK phospho-
rylation in a dose-dependent manner between 5 and 20
μM. However, further analyses revealed that the degree of
inhibition in these HCC cell lines was significantly differ-
ent according to their basal pERK expression levels. We
found that the sorafenib pERK inhibition effect in SMMC-
7721 cells, with lower pERK levels, was significantly
weaker than the other three HCC cell lines with relatively
higher basal pERK levels. On the contrary, no significant
change in pERK phosphorylation was observed after 5-FU
treatment.
It is possible that the antitumor activity of sorafenib might
be due to its ability to inhibit angiogenesis-related tyro-
sine kinases as well as other RAF/MEK/ERK-independent
mechanisms. For example, Raf-1 has been proposed to
induce the phosphorylation of proteins that control apop-
tosis independently of MEK and ERK [15]. Additionally,
the results of clinical trial analyses of sorafenib in renal
cell carcinoma and melanoma have not provided suffi-
cient information to conclude that the clinical value is
associated with inhibition of the RAF/MEK/ERK signaling
pathway [8].
However, positive results were observed in this study. In
cell viability assays, sorafenib inhibited proliferation of all
HCC cell lines with different basal pERK levels in a dose-
dependent manner. Furthermore, the effects of sorafenib
were significantly correlated with basal pERK levels in
these HCC cell lines by correlation analysis between the
IC50 values of sorafenib and their pERK density values,
indicating that sorafenib sensitivity could have direct links
with the activation of the RAF/MEK/ERK signaling path-
way and basal pERK levels in HCC tumor cells.
To more directly determine the relationship between
pERK expression and sensitivity to sorafenib, we used
U0126, a selective inhibitor of MEK 1/2, to inhibit theBMC Medicine 2009, 7:41 http://www.biomedcentral.com/1741-7015/7/41
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Effects of reducing basal pERK levels on sorafenib sensitivity Figure 5
Effects of reducing basal pERK levels on sorafenib sensitivity. (A, B) Immunocytochemical staining of pERK (200×) in 
MHCC97-H cells after treatment with 20 μM U0126 for 6 hours. (A) DMSO (0.1%) was used as solvent control. (B) U0126 20 
μM. (C) pERK expression was reduced after U0126 treatment in MHCC97-H cells. The expression rate of pERK was calcu-
lated from pERK density determined as described in Materials and methods and the rate in the control group was set as the 
100% baseline. Columns represent means from six samples in each group; bars indicate standard deviation; *, P < 0.05, Stu-
dent's t-test was used when compared with solvent control. (D) Effects of U0126 treatment for 6 hours on cell proliferation in 
MHCC97-H cells. (E) Effects of sorafenib individually and in sequential combination with U0126 on cell proliferation in 
MHCC97-H cells. In the sequential combination experiments, cells were pre-treated with 20 μM U0126 for 6 hours and then 
exposed to sorafenib for a further 24 hours. Each value represents the average of six independent determinations with four 
replicates per experiment; bars indicate standard error.BMC Medicine 2009, 7:41 http://www.biomedcentral.com/1741-7015/7/41
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MEK/ERK pathway and reduce basal pERK expression in
MHCC97-H cells without influencing cell proliferation.
We then assessed cellular responsiveness to sorafenib after
pERK down-regulation. The observations showed that the
pre-treated cells expressed much lower levels of pERK and
became significantly less sensitive to sorafenib-mediated
growth inhibition. These observations are perfectly con-
sistent with our hypothesis that the RAF/MEK/ERK signal-
ing pathway is essential for sorafenib-mediated growth
inhibition and that sensitivity to sorafenib is directly
related to the activation of this pathway and basal pERK
expression. These results also confirm the findings of
Ghassan K Abou-Alfa's group in a phase II clinical trial on
treating advanced HCC patients with sorafenib that found
that patients with tumors containing higher levels of
pERK were more sensitive, or responsive, to sorafenib,
supporting the notion that pERK may be a useful biomar-
ker in treating HCC with sorafenib [9]. In our opinion,
this was probably because blocking of the RAF/MEK/ERK
signaling pathway plays a central role in sorafenib antitu-
mor activity in HCC cells. As a key downstream compo-
nent of this pathway, pERK levels could reflect the
constitutive activity status of this signaling pathway, as
well as the degree of inhibition of this pathway by soraf-
enib. Our study provides further in vitro evidence that
pERK could be a useful biomarker predictive of a response
to sorafenib in HCC tumor cells.
Resistance to the traditional chemotherapy drug 5-FU was
closely associated with basal pERK expression in these
HCC cell lines. Thus, the RAF/MEK/ERK pathway may be
involved in the development of drug resistance to tradi-
tional chemotherapy in HCC, as reported in previous
studies in other types of cancer. For instance, in breast
cancer cells, activated Raf conferred resistance to the
chemotherapeutic drugs doxorubicin and paclitaxel by
inducing the expression of the drug pump Mdr-1 and the
Bcl-2 antiapoptotic protein [15]. The results reported here
would provide clues for further studies on reducing drug
resistance by blocking the RAF/MEK/ERK signaling path-
way and rationally combining sorafenib with other tradi-
tional cytotoxic agents to further improve efficacy.
Conclusion
These experiments demonstrate that the RAF/MEK/ERK
pathway might be involved in drug resistance to tradi-
tional chemotherapy in HCC cell lines. More importantly,
our study provides further in vitro evidence that pERK
could be a useful biomarker predictive of sensitivity to
sorafenib in HCC tumor cells.
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